stockportfolio.pro
Stocks / RXRX vs SNDX
RXRX vs SNDX
Recursion Pharmaceuticals, Inc. and Syndax Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Recursion Pharmaceuticals, Inc. (RXRX) | Syndax Pharmaceuticals, Inc. (SNDX) | |
|---|---|---|
| Market cap | $1.6B | $1.6B |
| Revenue (latest FY) | $74.26M | $172.35M |
| Net income (latest FY) | $-644.76M | $-285.42M |
| Revenue growth (5y CAGR) | 79.7% | 157.7% |
| Net margin | -868.3% | -165.6% |
| Return on equity | -57.0% | -441.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open RXRX — free Open SNDX — freeFrequently asked questions
Which is bigger, RXRX or SNDX?
Recursion Pharmaceuticals, Inc. is larger by market capitalization — $1.6B versus $1.6B.
Which grows faster, RXRX or SNDX?
Over the last five fiscal years, Syndax Pharmaceuticals, Inc. grew revenue faster — 157.7%/yr versus 79.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.